Results 131 to 140 of about 31,827 (245)
Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: A multi-centric prospective study. [PDF]
Billiet A +17 more
europepmc +1 more source
Soluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients
ABSTRACT Background and Aims Post liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long‐term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB‐4) score and FibroScan.
Emilie Høegholm Ernst Lauridsen +7 more
wiley +1 more source
Trans sigmoid colon NOTES sclerotherapy for polycystic liver disease. [PDF]
Liu T +6 more
europepmc +1 more source
Abstract Aims To evaluate the impact of obesity, with or without gestational diabetes mellitus (GDM), on adverse maternal outcomes and determine whether the combination of obesity and GDM confers a greater risk compared to obesity alone. Methods We systematically searched MEDLINE, EMBASE, Scopus, CINAHL and the WoS Core Collection, identifying 19 ...
Tessa L. Weir +2 more
wiley +1 more source
Polycystic Disease of Liver [PDF]
openaire +2 more sources
Transcatheter hepatic arterial embolization with metallic coils for polycystic liver disease
Takeshi Soyama
openalex +1 more source
Abstract Aim CD4 + CD25highCD127‐T regulatory cells (Tregs) remain a drug candidate for immunotherapy of type 1 diabetes. We completed three trials testing Tregs in recently diagnosed type 1 diabetes children. Here, we looked for long‐term safety and efficacy aspects important in the authorisation of this therapy.
Marta Bandura +18 more
wiley +1 more source
Tamoxifen for the treatment of polycystic liver disease: A case report. [PDF]
Aapkes SE +4 more
europepmc +1 more source

